Trastuzumab Rezetecan is a HER2-targeted antibody-drug conjugate (ADC). It combines trastuzumab (an anti-HER2 antibody) with rezetecan, a topoisomerase I inhibitor chemotherapy payload.
Trastuzumab Rezetecan
Generic Name/API:Trastuzumab Rezetecan
Packaging:Packaged in single-dose vials
Storage:Store at 2°C to 8°C
Dosage:For dosage information, please visit the General Information section.
Strength:100 mg single-dose vials
Indication:Trastuzumab Rezetecan is indicated for adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have human epidermal growth factor receptor 2 (HER2) [ERBB2]-activating mutations and have received ≥ 1 previous systemic treatment.
Trastuzumab Rezetecan (also known as SHR-A1811) is a novel antibody–drug conjugate consisting of a humanised HER2-directed monoclonal antibody, cleavable tetrapeptide-based linker, and DNA topoisomerase I inhibitor. It is being being developed by Jiangsu HengRui Medicine Co., Ltd. In May 2025, it was approved by the National Medical Products Administration of China for the treatment of adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have human epidermal growth factor receptor 2 (HER2) [ERBB2]-activating mutations and have received ≥ 1 previous systemic treatment.
STRENGTH:
100 mg single-dose vials
DOSAGE:
Trastuzumab Rezetecan was administered at 4·8 mg/kg intravenously once every 3 weeks according to Phase II clinical data.
ADVERSE EFFECTS:
Serious Adverse Events:
- Interstitial Lung Disease (ILD) and Pneumonitis.
- Severe Blood Counts
Most common and severe (Grade 3–4) treatment-related adverse events include:
- Neutropenia: Decreased neutrophil count.
- Leukopenia: Reduced white blood cell count.
- Anemia: Low red blood cell counts.
- Thrombocytopenia: Decreased platelet count .
- Gastrointestinal Issues.
STORAGE:
Vials should generally be refrigerated at 20 – 80 C (360 to 460 F).
Trastuzumab rezetecan (SHR-A1811) is a HER2-directed antibody-drug conjugate (ADC).
Like other topoisomerase I inhibitor ADCs, it has severe risks that require strict monitoring and precautions, primarily regarding lung toxicity, heart function, and embryo-fetal development.
The most critical risks associated with topoisomerase I-inhibitor ADCs include:
- severe lung inflammation (ILD/pneumonitis)
- embryo-fetal toxicity
- severe bone marrow suppression
- heart dysfunction.
FAQ
Is Trastuzumab Rezetecan approved?
It has been approved in China and continues to undergo clinical development in multiple regions. Regulatory status varies by country.
Who developed Trastuzumab Rezetecan?
It was developed by Jiangsu Hengrui Pharmaceuticals. In 2025, Glenmark Pharmaceuticals licensed rights for many international markets.
What are the important adverse effects being monitored?
As with other HER2 ADCs, investigators closely monitor:
- Interstitial lung disease (ILD)/pneumonitis
- Bone marrow suppression (neutropenia, anemia)
- Gastrointestinal toxicity
- Infusion-related reactions
What is the price of Trastuzumab Rezetecan in India?
The price of Trastuzumab Rezetecan in India depends on dosage, availability and import requirements. Contact 24/7QualityMeds at +91 9967979080 for the latest pricing information.
How to buy Trastuzumab Rezetecan in India?
To buy Trastuzumab Rezetecan in India, a valid prescription is generally required. Contact 24/7QualityMeds for availability, procurement and import assistance.
